Genvor Inc. (OTCQB: GNVR)

Genvor, Inc. (OTC: GNVR) is a biotechnology company pioneering peptide-based solutions for crop protection and plant health. With a focus on sustainable agriculture, Genvor develops and commercializes biological actives that enhance crop performance, reduce chemical inputs, and support regenerative farming systems. Through its partnerships and technology platforms, Genvor is advancing a new era of natural, science-based crop protection For more information, visit www.genvor.com.

OS Therapies Incorporated (NYSE American: OSTX)

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in the First Quarter of 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. 

Prostatype Genomics AB (OTCQB: PGABF | Nasdaq First North: PROGEN)

Prostatype® is a genetic test available to patients and treating urologists as a complementary decision-making tool when considering treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

EchoIQ Ltd. (OTCQB: ECHQF | ASX: EIQ)

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

Thiogenesis Therapeutics Corp. (OTCQX: TTIPF | TSXV: TTI)

Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis' lead product candidate, TTI-0102 has an active Phase 2 clinical trial in Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), an IND-cleared Phase 2a clinical trial planned in Leigh syndrome spectrum, a Phase 2 clinical trial planned in pediatric Metabolic Dysfunction-Associated Steatohepatitis ("MASH") and a Phase 3 clinical trial planned in nephropathic cystinosis.

Inmed Pharamaceuticals Inc. (NASDAQ: INM)

InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

BioCorRx Inc. (OTCQB: BICX)

BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Designed to address alcoholism and certain opioid addictions, the Beat Addiction Recovery Program is used by independent treatment centers or physicians in the United States. The program consists of BioCorRx’s proprietary cognitive behavioral therapy (CBT) program and peer recovery support mobile application and may include the use of certain medications typically used for the treatment of substance use disorder (SUD). Which medication used, if any, is at the sole discretion of the treating physician in consultation with their patient. The most common medication used in the program is naltrexone in various forms (oral, injectable, implantable pellet). The company does not sell, manufacture, or compound any drugs or pharmaceuticals. The company also has a pharmaceutical subsidiary, BioCorRx Pharmaceuticals, which is developing medications for future regulatory approval. It’s lead candidate is a biodegradable implantable naltrexone pellet for alcohol and opioid use disorders.

Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)

Amplia Therapeutics Limited, a pharmaceutical company based in Melbourne, Australia, focuses on development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and chronic fibrotic diseases. The company's lead product is narmafotinib (AMP945), a best-in-class inhibitor of FAK, currently undergoing clinical trials in advanced pancreatic cancer. Data from the Phase 1b/2a ACCENT trial run in Australia and Korea has been very positive and a new clinical trial is now opening in the US and Australia under an open IND. Additional opportunities in other cancers such as ovarian cancer, and in fibrotic diseases such as idiopathic pulmonary fibrosis, are also being explored based on promising preclinical data. Narmafotinib has Orphan Drug Designation and Fast-Track Designation from the US FDA for pancreatic cancer.

Defence Therapeutics Inc. (CSE: DTC | FSE: DTC | OTCQB: DTCFF)

Defence Therapeutics Inc. is a Canadian biotech company advancing precision oncology with itsproprietary Accum® platform. By overcoming a key barrier in intracellular drug delivery, Accum®makes cancer therapies, especially ADCs and radiopharmaceuticals, significantly more potent,safer, and cost-effective. With a strong IP portfolio, a de-risked licensing model, and strategicpartnerships, Defence is positioned for sustainable growth and long-term value creation.

ONWARD Medical N.V. (OTCQX: ONWRY | Euronext: ONWD)

ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC-EX® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs, including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.

Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).